142 related articles for article (PubMed ID: 35582012)
1. Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging.
Venkatesh C; Shen J; Putt KS; Low PS
Cancer Drug Resist; 2021; 4(1):223-232. PubMed ID: 35582012
[No Abstract] [Full Text] [Related]
2. Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
Proc Natl Acad Sci U S A; 2006 Sep; 103(37):13872-7. PubMed ID: 16950881
[TBL] [Abstract][Full Text] [Related]
3. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates.
Austin CD; Wen X; Gazzard L; Nelson C; Scheller RH; Scales SJ
Proc Natl Acad Sci U S A; 2005 Dec; 102(50):17987-92. PubMed ID: 16322102
[TBL] [Abstract][Full Text] [Related]
4. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the pH of folate receptor-containing endosomes and the rate of hydrolysis of internalized acid-labile folate-drug conjugates.
Yang J; Chen H; Vlahov IR; Cheng JX; Low PS
J Pharmacol Exp Ther; 2007 May; 321(2):462-8. PubMed ID: 17289839
[TBL] [Abstract][Full Text] [Related]
6. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
7. Development of a Cysteine-Conjugatable Disulfide FRET Probe: Influence of Charge on Linker Cleavage and Payload Trafficking for an Anti-HER2 Antibody Conjugate.
Scales SJ; Tsai SP; Zacharias N; Cruz-Chuh JD; Bullen G; Velasquez E; Chang J; Bruguera E; Kozak KR; Sadowsky J
Bioconjug Chem; 2019 Dec; 30(12):3046-3056. PubMed ID: 31726009
[TBL] [Abstract][Full Text] [Related]
8. Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Liu J; Kopecková P; Bühler P; Wolf P; Pan H; Bauer H; Elsässer-Beile U; Kopecek J
Mol Pharm; 2009; 6(3):959-70. PubMed ID: 19344119
[TBL] [Abstract][Full Text] [Related]
9. Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells.
Olatunji FP; Savoy EA; Panteah M; Mesbahi N; Abbasi A; Talley CM; Lovingier CL; Caromile LA; Berkman CE
Bioconjug Chem; 2021 Nov; 32(11):2386-2396. PubMed ID: 34699177
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
11. Tagging Transferrin Receptor with a Disulfide FRET Probe To Gauge the Redox State in Endosomal Compartments.
Bi X; Yin J; Zhang D; Zhang X; Balamkundu S; Lescar J; Dedon PC; Tam JP; Liu CF
Anal Chem; 2020 Sep; 92(18):12460-12466. PubMed ID: 32686399
[TBL] [Abstract][Full Text] [Related]
12. Intracellular delivery and antitumor effects of a redox-responsive polymeric paclitaxel conjugate based on hyaluronic acid.
Yin S; Huai J; Chen X; Yang Y; Zhang X; Gan Y; Wang G; Gu X; Li J
Acta Biomater; 2015 Oct; 26():274-85. PubMed ID: 26300335
[TBL] [Abstract][Full Text] [Related]
13. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
14. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
Xiang B; Dong DW; Shi NQ; Gao W; Yang ZZ; Cui Y; Cao DY; Qi XR
Biomaterials; 2013 Sep; 34(28):6976-91. PubMed ID: 23777916
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Tumor Uptake of Triazine Dendrimers Decorated with Four, Sixteen, and Sixty-Four PSMA-Targeted Ligands: Passive versus Active Tumor Targeting.
Lim J; Guan B; Nham K; Hao G; Sun X; Simanek EE
Biomolecules; 2019 Aug; 9(9):. PubMed ID: 31466360
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer.
Bandari RP; Jiang Z; Reynolds TS; Bernskoetter NE; Szczodroski AF; Bassuner KJ; Kirkpatrick DL; Rold TL; Sieckman GL; Hoffman TJ; Connors JP; Smith CJ
Nucl Med Biol; 2014 Apr; 41(4):355-63. PubMed ID: 24508213
[TBL] [Abstract][Full Text] [Related]
18. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen.
Liu T; Wu LY; Kazak M; Berkman CE
Prostate; 2008 Jun; 68(9):955-64. PubMed ID: 18361407
[TBL] [Abstract][Full Text] [Related]
19. Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Kumar A; Mastren T; Wang B; Hsieh JT; Hao G; Sun X
Bioconjug Chem; 2016 Jul; 27(7):1681-9. PubMed ID: 27248781
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies.
Matthias J; Engelhardt J; Schäfer M; Bauder-Wüst U; Meyer PT; Haberkorn U; Eder M; Kopka K; Hell SW; Eder AC
Cancer Res; 2021 Apr; 81(8):2234-2245. PubMed ID: 33622696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
